We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
-7.79%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$1.24B
AUM Growth
+$7.74M
Cap. Flow
+$112M
Cap. Flow %
8.99%
Top 10 Hldgs %
54.36%
Holding
75
New
18
Increased
14
Reduced
16
Closed
18

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$51.7M
2
RVMD icon
Revolution Medicines
RVMD
+$44.9M
3
MRUS
Merus
MRUS
+$41.2M
4
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$31.8M
5
IRON icon
Disc Medicine
IRON
+$31.4M

Top Sells

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$58.5M
2
DYN icon
Dyne Therapeutics
DYN
+$42.6M
3
IMVT icon
Immunovant
IMVT
+$34.1M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$32.1M
5
GERN icon
Geron
GERN
+$29.7M

Sector Composition

Rank Sector Weight
1 Healthcare 69.8%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
26
Ionis Pharmaceuticals
IONS
$9.33B
$14.3M 1.15%
+300,000
New +$12.3M
STOK icon
27
Stoke Therapeutics
STOK
$1.84B
$14.2M 1.14%
+1,050,000
New +$14.2M
ERAS icon
28
Erasca
ERAS
$6.68B
$13.9M 1.12%
+5,900,000
New +$12.7M
ELVN icon
29
Enliven Therapeutics
ELVN
$3.87B
$13.9M 1.12%
595,000
-979,220
-62% -$20.6M
SYRE icon
30
Spyre Therapeutics
SYRE
$8.65B
$13.5M 1.09%
575,000
+325,000
+130% +$11M
ENGN icon
31
enGene Therapeutics
ENGN
$121M
$11.3M 0.91%
1,200,000
+400,000
+50% +$5.13M
HELP
32
Cybin Inc
HELP
$481M
$10.8M 0.87%
1,052,632
– –
SKYE icon
33
Skye Bioscience
SKYE
$22.8M
$10.4M 0.84%
+1,301,518
New +$15.4M
ELEV
34
DELISTED
Elevation Oncology
ELEV
$10.4M 0.84%
3,850,000
+2,850,000
+285% +$10.7M
DYN icon
35
Dyne Therapeutics
DYN
$4.16B
$9.35M 0.75%
265,000
-1,465,000
-85% -$42.6M
FULC icon
36
CALL
Fulcrum Therapeutics
FULC
$247M
$9.3M 0.75%
1,500,000
+500,000
+50% +$3.79M
BHVN icon
37
Biohaven
BHVN
$2.17B
$8.68M 0.7%
+250,000
New +$9.88M
RLAY icon
38
Relay Therapeutics
RLAY
$4.07B
$8.48M 0.68%
+1,300,000
New +$8.88M
TRVI icon
39
Trevi Therapeutics
TRVI
$2.54B
$8.34M 0.67%
2,800,000
+600,000
+27% +$1.67M
RCKT icon
40
Rocket Pharmaceuticals
RCKT
$358M
$7.54M 0.61%
350,000
-950,000
-73% -$21.8M
ANNX icon
41
CALL
Annexon
ANNX
$860M
$7.35M 0.59%
1,500,000
+500,000
+50% +$2.59M
CMPS
42
Compass Pathways
CMPS
$1.52B
$7M 0.56%
1,159,030
+901,050
+349% +$7.09M
AVTX icon
43
Avalo Therapeutics
AVTX
$1.01B
$6.72M 0.54%
+539,079
New +$6.99M
LCTX icon
44
Lineage Cell Therapeutics
LCTX
$252M
$4.69M 0.38%
4,700,000
-1,550,000
-25% -$1.71M
ATYR
45
aTyr Pharma
ATYR
$48M
$4.68M 0.38%
3,000,000
-100,000
-3% -$174K
ATXS
46
DELISTED
Astria Therapeutics
ATXS
$4.55M 0.37%
500,000
-744,960
-60% -$7.27M
RAPP
47
Rapport Therapeutics
RAPP
$2B
$4.37M 0.35%
+208,910
New +$4.84M
NXTC icon
48
NextCure
NXTC
$19.7M
$3.98M 0.32%
208,333
+47,916
+30% +$932K
NMRA icon
49
Neumora Therapeutics
NMRA
$293M
$2.95M 0.24%
300,000
-82,345
-22% -$852K
ALLK
50
DELISTED
Allakos
ALLK
$2.9M 0.23%
2,900,000
– –
1
2
3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q2 2024 Portfolio in Review

As of Q2 2024, Logos Global Management held 75 positions worth $1.24B, up 0.63% from $1.24B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Logos Global Management deployed $112M of net new capital in Q2 2024, opening 18 new positions and adding to 14 existing holdings. Its largest new stake was argenx: 135,000 shares worth $58.1M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 77% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Dyne Therapeutics, an estimated $42.6M trimmed.

  • Logos Global Management's largest Q2 2024 buy was argenx: 135,000 shares worth $58.1M.
  • Logos Global Management added most to Janux Therapeutics in Q2 2024, an estimated $28.2M increase.
  • Logos Global Management's biggest Q2 2024 reduction was Dyne Therapeutics, cutting an estimated $42.6M.
  • Logos Global Management fully exited Immunocore in Q2 2024, selling an estimated $58.5M.
  • Logos Global Management's ten largest holdings make up 54% of its $1.24B portfolio in Q2 2024.
  • Logos Global Management opened 18 new positions and closed 18 in Q2 2024.
  • Logos Global Management's portfolio value rose 0.63% quarter-over-quarter to $1.24B.

Based on Logos Global Management's 13F filing for Q2 2024, filed 14 Aug 2024.